[pT1G3 bladder carcinoma: parameters of a correct therapy]

Arch Ital Urol Androl. 1996 Feb;68(1):17-20.
[Article in Italian]

Abstract

Between 13.8% and 27% of all superficial bladder cancers are represented by pT1G3 neoplasm. In the Department of Urology of Policlinico S. Marco-Zingonia, between February 1988 and June 1994, we treated 22 patients suffering for pT1G3 bladder tumor. TUR-B has demonstrated to be a good approach for treatment of superficial bladder cancer, with low morbility; on the opposite side, we have to underline the high rate of recurrence and of progression of the urothelium disease. Now a day our best approach for the treatment of pT1G3 bladder tumor is represented by radical cystectomy supplied by chemotherapy.

Publication types

  • Comparative Study
  • English Abstract

MeSH terms

  • BCG Vaccine / administration & dosage
  • Carcinoma, Transitional Cell / pathology
  • Carcinoma, Transitional Cell / surgery
  • Carcinoma, Transitional Cell / therapy*
  • Chemotherapy, Adjuvant
  • Combined Modality Therapy
  • Cystectomy
  • Female
  • Follow-Up Studies
  • Humans
  • Lymph Node Excision
  • Male
  • Middle Aged
  • Neoplasm Recurrence, Local
  • Prognosis
  • Time Factors
  • Urinary Bladder / pathology
  • Urinary Bladder Neoplasms / pathology
  • Urinary Bladder Neoplasms / surgery
  • Urinary Bladder Neoplasms / therapy*

Substances

  • BCG Vaccine